LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

Search

Pacific Biosciences of California Inc

Geschlossen

BrancheGesundheitswesen

1.76 -6.38

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.76

Max

1.88

Schlüsselkennzahlen

By Trading Economics

Einkommen

3.9M

-38M

Verkäufe

-1.3M

38M

EPS

-0.12

Gewinnspanne

-98.853

Angestellte

575

EBITDA

3.2M

-32M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+35.59% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-123M

549M

Vorheriger Eröffnungskurs

8.14

Vorheriger Schlusskurs

1.76

Nachrichtenstimmung

By Acuity

50%

50%

157 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Pacific Biosciences of California Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Dez. 2025, 21:41 UTC

Akquisitionen, Fusionen, Übernahmen

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

26. Dez. 2025, 20:22 UTC

Market Talk

Oil Loses Ground On Russia-Ukraine Peace Efforts -- Market Talk

26. Dez. 2025, 20:13 UTC

Market Talk

U.S. Natural Gas Gains on Colder Weather Outlook -- Market Talk

26. Dez. 2025, 19:24 UTC

Akquisitionen, Fusionen, Übernahmen

Nvidia's Groq Deal Is an Instagram Moment -- With 1 Big Risk -- Barrons.com

26. Dez. 2025, 17:45 UTC

Market Talk

U.S. Diesel Down on Lower Crude Prices, Freight-Sector Lull -- Market Talk

26. Dez. 2025, 15:52 UTC

Market Talk

Oil Futures Turn Lower After Steady Start -- Market Talk

26. Dez. 2025, 14:58 UTC

Market Talk

Silver, Gold Reach New Highs Amid Geopolitical Tension -- Market Talk

26. Dez. 2025, 14:41 UTC

Market Talk

U.S. Natural Gas Futures Look to End Week Higher -- Market Talk

26. Dez. 2025, 14:28 UTC

Market Talk

Dollar Indexes Flat as Yen Rally Wanes -- Market Talk

26. Dez. 2025, 13:47 UTC

Market Talk

Oil Futures Steady in Thin Holiday Trade -- Market Talk

26. Dez. 2025, 07:22 UTC

Market Talk

Comex Gold Futures' Strong Bullish Momentum in Play, Chart Shows -- Market Talk

26. Dez. 2025, 05:03 UTC

Market Talk

Malaysian Ringgit Likely to Face Pressure From Dollar Strength in 1Q -- Market Talk

26. Dez. 2025, 03:38 UTC

Market Talk

Global Equities Roundup: Market Talk

26. Dez. 2025, 03:38 UTC

Market Talk

Korean Won Strengthens, Supported by Verbal Interventions -- Market Talk

26. Dez. 2025, 02:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

26. Dez. 2025, 02:44 UTC

Market Talk

Singapore Dollar Weakens Slightly on Likely Position Adjustments -- Market Talk

26. Dez. 2025, 01:39 UTC

Market Talk

China's Central Bank Signals Possibility of Easing Policy in Coming Months -- Market Talk

26. Dez. 2025, 01:14 UTC

Market Talk

Oil Edges Higher Amid Geopolitical Tensions -- Market Talk

26. Dez. 2025, 00:34 UTC

Market Talk

Yen Mostly Weakens Amid Risk-on Sentiment -- Market Talk

26. Dez. 2025, 00:15 UTC

Market Talk

Nikkei Gains 0.6%, Led by Tech, Videogame Stocks -- Market Talk

25. Dez. 2025, 23:42 UTC

Market Talk

Nikkei May Trade in Range; Yen in Focus -- Market Talk

25. Dez. 2025, 23:40 UTC

Market Talk

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

25. Dez. 2025, 00:20 UTC

Akquisitionen, Fusionen, Übernahmen

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

24. Dez. 2025, 22:22 UTC

Akquisitionen, Fusionen, Übernahmen

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24. Dez. 2025, 21:26 UTC

Akquisitionen, Fusionen, Übernahmen

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

24. Dez. 2025, 19:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. Dez. 2025, 19:35 UTC

Market Talk

Treasury Yields Decline Ahead of Christmas -- Market Talk

24. Dez. 2025, 19:09 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Global Equities Roundup: Market Talk

24. Dez. 2025, 19:09 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

24. Dez. 2025, 19:06 UTC

Market Talk

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

Peer-Vergleich

Kursveränderung

Pacific Biosciences of California Inc Prognose

Kursziel

By TipRanks

35.59% Vorteil

12-Monats-Prognose

Durchschnitt 2.4 USD  35.59%

Hoch 3 USD

Tief 2 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pacific Biosciences of California Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

5 ratings

3

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

1.13 / N/AUnterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

157 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat